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Abstract
Background: The authors present their own experience of the treatment of patients qualified for transcatheter 
aortic valve implantation (TAVI) carried out in a modern hybrid operating room. The objective of the present study 
was to demonstrate the initial results of conducting anaesthesia in high-risk patients qualified for the TAVI procedure 
(transcatheter aortic valve implantation). In addition, the authors’ aim was also to point out to the special challenges 
of an anaesthesiologist conducting local anaesthesia in such a type of procedures and to evaluate the safety and 
efficacy of the TAVI procedure conducted under remifentanil analgosedation.
Methods: A retrospective analysis included patients treated during the period from September 2015, when local 
anaesthesia for the transcatheter aortic valve implantation was used for the first time at our centre, up to February 
2016. The studied population consisted of 11 patients treated for severe aortic valve stenosis. The mean age of patients 
was 80 ± 7 years. Three patients were men (27%) and eight were women (73%). The study included all subsequent 
patients (n = 11), treated in our centre, for whom it was decided to perform TAVI under local anaesthesia. 
Results: The total hospital mortality rate was 0%. All procedures were performed in a hybrid operating room. Despite 
the complications observed in the described group, the hospital mortality rate during TAVI was 0%. All patients, after 
12 ± 5 days of treatment, left the hospital in a good neurological condition, which was assessed based on the CPC-1 
(Cerebra Performance Categories Scale) and GCS-15 (Glasgow Coma Scale) scales. With an ejection fraction of the 
left ventricle of 53 ± 11%, the transcatheter aortic valve was successfully implanted. 
Conclusions: Percutaneous aortic valve implantation can be successfully conducted under remifentanil analgose-
dation. TAVI procedures should be performed in the conditions of a modern, well-equipped hybrid room. The aim 
of the anaesthesiologist should consist of conducting the least invasive anaesthesia/analgesia, bearing in mind the 
safety and comfort of the patient.
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Transcatheter aortic valve implantation (TAVI) has 
provided a therapeutic alternative for symptomatic 
patients with severe aortic stenosis [1].  Severe aor-
tic valve stenosis is defined in an integrated manner 
taking into consideration the aortic valve exit sur-
face area (< 1.0 cm2 or < 0,6 cm2*m-2 BSA except for 
obese patients) and flow-dependent indices (maxi-
mum flow velocity of 4 m s-1 through the valve and 
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mean aortic gradient ≥ 40 mm Hg). Severe aortic 
valve stenosis is a well-known mortality risk factor [2]. 
Currently, surgical aortic valve replacement (AvR) is 
the treatment of choice for a  large majority of pa-
tients with severe aortic valve stenosis [3]. However, 
nearly 30% of older patients with numerous coex-
isting diseases are considered not to be eligible for 
surgical treatment due to perioperative mortality [4]. 
Transcatheter aortic valve implantation (TAVI), a new 
method of severe aortic valve stenosis which has been 
introduced recently, has dynamically developed and 
minimised surgical trauma related to cardiac arrest, 
sternotomy, or the use of extracorporeal circulation 
in high-risk patients [5–8]. The experience of centres 
that have conducted transcatheter aortic valve im-
plantation is still growing. Many of these centres have 
abandoned general anaesthesia and transesophageal 
sonography and are performing procedures with lo-
cal anaesthetization or sedation [9–11]. The first TAVI 
in Poland was conducted at our centre in 2008. Since 
then, a considerable technological advancement has 
taken place in terms of implanted valves, while the 
way of treating patients during periprocedureal pe-
riod is being continuously improved. 
The objective of this study was to evaluate the 
safety and efficacy of the TAVI procedure conducted 
with remifentanil analgosedation. 
METHODS
Patients
The study was conducted following the Declaration 
of Helsinki. The preparation of this manuscript was 
approved by the management of the local hospital. 
The study included all subsequent patients treated at 
the Anaesthetics and Intensive Care Unit of the Clinical 
Department of Cardiovascular Surgery and Transplan-
tation of the Jagiellonian University in Krakow, who 
were qualified for the TAVI procedure under local an-
aesthesia. The analysis included a group of 11 patients 
treated during the period from September 2015, when 
the first TAVI in local anaesthesia was conducted in our 
clinic, up to February 2016. The retrospective analy-
sis included demographical data, coexisting disease, 
valve sonogram prior and after TAVI, procedure time, 
fluoroscopy, valve type, ejection fraction of the left 
ventricle after acceptance to the hospital, troponin 
profile, time of hospital stay, intensive care time, as well 
as complications occurring during treatment. 
Methods
Transcatheter aortic valve implantation proce-
dures were carried out in a  hybrid operating room 
which is an operating theatre with an integrated an-
giogram, where endovascular or intracardiac proce-
dures are carried out. Our centre has the Artiz Zeego 
(Siemens, Germany) angiogram at its disposal. The 
hybrid operating room constitutes a  combination 
of a conventional operating theatre and a room for 
percutaneous procedures and haemodynamic study. 
The room is fitted with high-end technology equip-
ment. The X-ray machine, installed on a c-arm, pivots 
360 degrees, enabling precise imaging, and thus al-
lowing angiographic, subtractional and tomographic 
examinations. The hybrid room is equipped with an 
anaesthetization station that fully monitors vital func-
tions, enabling the safe performance of analgesia, 
analgosedation, as well as general anesthetization. 
The procedures were carried out by interventional 
cardiologist, with the active participation of a cardiac 
surgeon, radiology technician and perfusionist. The 
course of analgosedation was supervised by an anaes-
thesiologist, along with an anaesthesiological nurse. 
The retrospective analysis included patients treated 
during the period from September 2015, when local 
anaesthesia for transcatheter aortic valve implanta-
tion was used for the first time at our centre, up to 
February 2016. The studied population consisted of 
11 patients treated for severe aortic valve stenosis. 
The study included all subsequent patients (n = 11), 
treated at our centre, for whom it was decided to 
perform TAVI under local anaesthesia. The routine 
monitoring included a five-point electrocardiogram 
with an automatic analysis of the ST segment, pulse 
oxymetry, direct blood pressure measurement via 
a cannula inserted in the radial artery (usually right), 
transthoracic echocardiography and hourly diuresis 
via a Foley catheter inserted in the urinary bladder. 
Prior to the procedure, patients were inserted with two 
peripheral cannulas. One of these was intended for 
propofol (Fresenius Kabi, Deutschland) and remifen-
tanil (Ultiva, Glaxo, Anglia) infusion, whereas the other 
one was for liquid infusion. In ten patients, an endo-
cardial lead was inserted into the right ventricle, while 
in two patients, it was decided to insert the central 
injection for the measurement of the central venous 
pressure (CVP). All patients were supplied with passive 
oxygen therapy via face mask with an oxygen flow of 
4–5 L min-1. Analgesia was conducted by continuous 
infusion of an ultra-short-acting remifentanil opioid 
in doses 0.05–0.08 mg kg-1 min-1; a few patients were 
continuously infused with propofol (Fresenius Kabi, 
Germany) in doses 4–12 mg kg-1 h-1. During the pro-
cedure, a standard liquid infusion was used (12–15 mL 
kg-1 h-1) in order to maintain haemodynamic stability. 
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Table 1. General characteristics of patients
Patients 1 2 3 4 5 6 7 8 9 10 11 Median Interqartile  
range
Age (years) 80 87 77 79 82 87 82 85 80 63 75 80 8
Sex F F F F F F F F M M M 3 (M) –
IM Yes Yes Yes Yes Yes Yes Yes Yes No Yes No 9 –
PCI Yes Yes Yes Yes Yes Yes No Yes No Yes No 8 –
CABG No No Yes No No No No No No Yes No 2 –
Stroke No No Yes No No No No No No No No 1 –
Diabetes No Yes No Yes No No Yes No Yes No No 4 –
Weight
(kg)
73 62 78 66 73 68 63 75 76 74 106 73 10
Height 158 168 161 157 153 152 149 163 167 169 160 160 14
BMI
(kg cm-2)
29.2 22.0 30.1 26.8 31.2 29.4 28.4 28.2 27.3 25.9 41.4 28.4 3.30
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IM — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery bypass graft; MIC — morbus ishemicus cordis; HA — hypertonia arterialis; 
FA — flagelatio atriorum; COPD — chronic obstructive pulmonary disease; UGIT — upper gastrointestinal tract; CRI — chronic renal insufficiency; DDD — atrioventricular 
stimulation inhibited by the appropriate rhythm of the atria and/or ventricles
Two external defibrillator electrodes were installed 
on the chest of each patients. Moreover, each patient 
had two units of packed red blood cells crossed and 
reserved for the periprocedureal period.
Heparin was administered during the procedure in 
order to obtain an activated coagulation time (ACT) of 
250 seconds. In our study, prostheses of the following 
valves were implanted: Lotus Valve System (Boston 
Scientific), Sapien 3 (Edwards) and Core Valve Evolut 
R (Medtronic). 
Prior to uncovering the artery, local anaesthesia 
with 1% lidocaine – was infused in the area of the 
right and left groins. The femoral artery was surgically 
uncovered and then injected undera visual supervi-
sion. The injection site was secured by a purse-string 
closure. After the procedure, all patients were trans-
ferred to the intensive care unit for further monitoring.
statistical analysis
Statistical analysis was conducted using STATIS-
TICA 10 PL software. The median and interquartile 
ranges were calculated for quantitative variables. Rela-
tive values were provided for the analysis of qualitative 
variables.
RESulTS
The authors report their first experiences in con-
ducting transcatheter aortic valve implantation un-
der analgosedation at their centre. Table 1 presents 
demographic data and general characteristics of the 
studied groups with coexisting diseases. The studied 
population consisted of 11 patients treated for severe 
aortic valve stenosis. The mean patient age was 80. 
Three patients were men and eight were women. 
The study included all subsequent patients (n = 11), 
treated at our centre, for whom it was decided to per-
form TAVI under local anaesthesia. The total hospital 
mortality rate was 0%.
Patient characteristics in the immediate preop-
erative period are shown in Table 2. The majority of 
patients (n = 9) were classified under class NYHA III 
(New York Heart Association). One patient was in class 
Other
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Table 2. Patient characteristics in the immediate preoperative period
Patients 1 2 3 4 5 6 7 8 9 10 11 Median Interqartile 
range
Angina class —  1 CCS X 1 –
Angina class —  2 CCS X X X X X X X 7 –
Angina class —  3 CCS X X X 3 –
NYHA class II X 1 –
NYHA class III X X X X X X X X X 9 –
NYHA class IV X 1 –
LVEF (%) 35 50 60 65 60 40 60 68 30 35 35 50.000 25.000
Peak gradient 79 100 75 80 107 70 80 85 72 24 63 79.000 15.000
Average gradient 48 60 50 50 71 43 47 48 42 14 37 48.000 8.000
Surface area (cm-2) 0.7 0.7 0.6 0.9 0.5 0.6 0.9 0.7 0.9 1.3 0.8 0.700 0.300
Logistic EuroScore 42% 27% 45% 12% 15% 27% 15% 15% 15% 14% 16% – –
CCS — Canadian Cardiovascular Society; NYHA — New York Heart Association; LVEF — left ventricular ejection fraction
NYHA II and one in NYHA IV. The mean left ventricle 
ejection fraction was 50. Except for one patient, all 
patients exhibited severe aortic valve stenosis with 
an exit surface area of below 1 cm2. In a patient with 
a valve surface area of 1.8 cm2, a transfemoral aortic 
valve implantation with Medtronic Corevalve 31 mm 
had been performed three years earlier. Due to severe 
aortic regurgitation, the cardiology team decided to 
implant a new type of valve, namely “valve-in-valve”. 
On the day before the procedure, the consulting 
anaesthesiologist classified all patients under group IV 
based on the ASA scale (American Society of Anesthe-
siologists), which means that these patients suffered 
from severe systemic diseases that were life-threaten-
ing. The precise time of each procedure and intraoper-
ative variables are presented in Table 3. Three patients 
in the direct postoperative period were administered 
with catecholamines. In only one patient were vaso-
dilators used. The mean time of intensive care was 
24 hours. However, at this point it should be empha-
sised that nine patients were admitted to the intensive 
care unit due to the necessity of monitoring the basic 
vital functions and prophylactic action against pos-
sible TAVI complications. Although the state of the 
patients while admitted to the intensive care unit was 
stable, one patient (a woman) was admitted in shock, 
and in whom symptoms of atrioventricular block were 
observed during the procedure. Despite the insertion 
of a prophylactic endocavitary probe, cardiac arrest 
may occur. In such cases, an indirect heart massage 
and conversion from analgosedation to general anaes-
thesia should be performed immediately. In our study, 
one patient required a 48-hour stay at the intensive 
care unit, in whom conversion from analgosedation 
to general anaesthesia was performed due to a lack 
of coprocedure. The postoperative characteristics of 
the reported group are presented in Table 4. 
Despite the complications that occurred in the 
described group, the hospital mortality rate of TAVI 
was 0%. As shown in Table 5, all patients after 9 days 
of treatment left the hospital in a good neurological 
condition, which was assessed based on the CPC-1 
(Cerebral Performance Categories Scale) and GCS-15 
(Glasgow Coma Scale) scales. With an ejection fraction 
of the left ventricle of (mean) 60%, a  transcatheter 
aortic valve was successfully implanted. 
In our study, a pacemaker was implanted in two 
patients due to third-degree atrioventricular block. 
In one patient, it was necessary to open the thorax 
medially and perform a heart tamponade decompres-
sion. No complications described in the literature oc-
curred, such as stroke, aortic dissection, aortic perfora-
tion, myocardial infarction, coronary vessel damage, 
haemodynamic instability requiring the introduction 
of extracorporal circulation or complications related 
to the peripheral vessels [12–14]. In two cases, it was 
necessary to convert local anaesthesia to general an-
aesthesia. 
DISCuSSION
The transcatheter aortic valve implantation (TAVI) 
is an innovative and rapidly developing technique 
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Table 3. Intraoperative variables for each patient
Patients 1 2 3 4 5 6 7 8 9 10 11 Median Interqartile 
range
ASA IV IV IV IV IV IV IV IV IV IV IV 11 –
GFR 63 57 84 62 28 61 66 33 44 60 79 61.000 22.000
Duration of the 
surgery
90 250 90 160 75 80 100 80 110 70 80 90.000 30.000
Ultiva Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 11 –
Propofol Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 10 –
CVC Yes Yes No No No No No No No No No 2 –
Endoscopic 
electrode 
sheath
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 10 –
Size of the 
prosthesis
23 25 23 23 23 27 23 23 27 29 31 – –
Duration of 
fluoroscopy
16 22 19 34 13 13 15 17 20 11 17 17.000 7.000
Absorbed dose 
(mGy)
232 162 826 1842 486 1197 439 1232 957 499 1831 826.000 793.000
ASA — American Society of Anaesthesiology; GFR — glomerular filtration rate; CVC — central venous catheter
Table 4. Postoperative characteristics of the reported group
Patients 1 2 3 4 5 6 7 8 9 10 11 Median Interqartile 
range
Presion drugs No Adr, DB, 
Lev
No DB No No No No No No DB 3 –
Vasodilators No No No No No No No No Yes No No 1 –
Max lactate 
concentration
0.6 5.5 0.9 1.0 0.7 1.3 1.3 0.8 0.9 0.8 2.6 0.900 0.500
Max. hsTnT 0.08 0.38 0.54 0.39 0.07 0.26 0.12 0.20 0.20 0.03 0.21 0.200 0.300
Max. CK-MB 13 32 55 25 22 37 21 13 18 29 23 23.000 14.000
GFR after the 
surgery
56 45 84 86 43 74 61 38 65 70 85 65.000 39.000
Stay in the ICU 
(h)
20 6 days 20 48 24 24 20 24 20 16 24 24.000 4.000
Hospital stay 
(days)
9 13 9 24 18 9 10 9 8 9 14 9.000 5.000
hs TnT — high-sensitive troponin T; CK-MB — creatine kinase–myocardial band
which has been available at our centre since 2008. It 
is considered as an alternative to conventional open 
heart surgery. Patients qualified for the procedure of 
aortic valve replacement but with high risk of hos-
pital mortality (EuroScore) [15, 16] may be qualified 
for this minimally invasive procedure. Until 2015, 
the procedures at our centre were conducted using 
general anaesthesia and very often on elderly pa-
tients with numerous burdens (most commonly ASA 
IV); such patients constitute a real challenge for the 
anaesthesiologist. The majority of patients after the 
transcatheter aortic valve implantation demonstrate 
a considerable increase in their quality of life [17]. The 
authors report their first experiences of the treatment 
of patients qualified for the TAVI procedure under local 
anaesthesia along with analgosedation. The anaes-
thetists used analgosedation and successfully led all 
patients through the perioperative period. It should 
be emphasised that besides the perfect coprocedure 
of cardiovascular teams, the success of the treatment 
significantly depends upon a modern and extensively 
equipped hybrid procedures room, functioning within 
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Table 5. Patient characteristics at hospital discharge
Patients 1 2 3 4 5 6 7 8 9 10 11 Median Interqartile 
range
LVEF (%) 50 70 60 60 60 50 60 60 35 35 45 60.000 15.000
Peak 
gradient
26 12 24 22 20 23 24 16 22 11 16 22.000 8.000
Average 
gradient
14 7 15 12 12 11 12 10 15 8 10 12.000 4.000
IA No No Slight No No Slight Slight Slight No No Slight – –
CPC  1 1 1 1 1 1 1 1 1 1 1 11 –
GCS 15 15 15 15 15 15 15 15 15 15 15 11 –
Compli-
cations
No SCA I effective 
resuscitation 
during 
implantation.
Conversion 
to general 
anaesthesia. 
Tamponade, 
median 
thoracotomy, 
implantation 
ICD
No Conversion 
to general 
anaesthesia 
due to lack 
of patient’s 
cooperation.
No No No No No No Block A–V, 
Implantation 
DDD
– –
LVEF — left ventricular ejection fraction; IA — aortic insufficiency; CPC — Cerebra Performance Categories Scale; GCS — Glasgow Coma Scale; SCA — sudden cardiac 
arrest; ICD — implantable cardioverter–defibrillator; A-V — atrio-ventricularis
the operating theatre. The anaesthesiologist has to 
have an anesthetization station at his disposal while 
the perfusionist must be able to allow the connexion 
of the artificial heart-lung apparatus. 
It should be emphasised that the study possesses 
several significant limitations. First, this is a non-ran-
domised study while the data were obtained from 
medical documentation. Second, a  significant limi-
tation is that only a  small number of patients par-
ticipated in this study, and hence, it appears to be 
legitimate to continue this study and observe the 
treatment results for a larger number of patients. Bear-
ing in mind the number of examined patients, certain 
useful, clinical trends were observed in this study. The 
authors have demonstrated that patients can be safely 
led through the TAVI procedure under remifentanil 
analgosedation. Not all patients qualified for the TAVI 
procedure have to be subjected to general anaesthe-
sia. This applies only to patients implanted with Core 
Valve Evolut R (Medtronic), Sapien 3 (Edwards) as well 
as Lotus Valve System (Boston Scientific) valves. TAVI 
procedure analgosedation constitutes a great chal-
lenge for the anaesthetist, who, in coprocedure with 
cardiac surgeon, should bear in mind the possible 
life-threatening complications. 
The literature reports available regarding the use 
of local anaesthesia along with analgosedation in pa-
tients qualified for TAVI are non-randomised in nature. 
The majority of them are observational studies and 
case series. Opinions of the researchers differ based 
on the type of anaesthesia used. A literature review 
demonstrates certain regularity. The centres, where 
TAVI procedures were performed for the first time, 
usually conducted them under general anaesthesia. 
Moreover, local anesthetization has begun to prevail 
over general in centres that have years of experience 
with TAVI procedures. Supporters of general anaesthe-
sia mention as a benefit, for example, the possibility 
of conducting transesophageal ultrasonography and 
the comfort of the operator which stems from the 
fact of working with an anesthetised and paralysed 
patient, and which allows for the precise placement 
of the valvular prosthesis [18].
Behan et al. [19] emphasised that in the majority of 
cases, TAVI may be conducted under analgosedation. 
They point to the fact that the use of local anaesthesia 
needs only a shorter hospital stay and that patients 
tolerate analgosedation better than general anaes-
thesia. Mayr et al. [20] stated that both local anesthe-
tization and general anaesthesia can be successfully 
used for TAVI. The type of anesthetization to be used 
should be decided by the ‘Heart Team’, and sedation 
should be conducted by an experienced anaesthetist. 
Maas et al. [21] carried out a meta-analysis of data 
from 5,919 patients. They demonstrated that neither 
mortality nor the incidence of major adverse cardiac 
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and cerebrovascular events after TAVI is affected by the 
choice of either local anaesthesia or general anaesthe-
sia. The lack of relationship between mortality and the 
type of anaesthesia selected was also demonstrated 
by Dall’Ara et al. [22]. 
CONCluSIONS
According to the authors, percutaneous aortic valve 
implantation may be successfully conducted under 
remifentanil analgosedation. TAVI procedures should 
be performed in a modern, well-equipped hybrid op-
erating room. The aim of the anaesthesiologist should 
consist of conducting the least invasive anaesthesia/ 
/analgesia, bearing in mind the safety and comfort of 
the patient. Conversion to general anaesthesia may 
be necessary in case of intraoperative complications. 
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